Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
HNGE affiliate reported a proposed sale of securities under a Form 144. The filing lists a 10b5-1 sale by James Budge of 14,763 shares on 02/23/2026 with gross proceeds of $580,736.79. The broker is listed as Morgan Stanley Smith Barney LLC.
James Pursley reported a sale of 15,000 common shares. The filing shows 15,000 shares sold under a 10b5-1 plan on 02/23/2026 for $589,983. The securities originated as Performance Stock Units granted 04/01/2023 and the broker listed is Morgan Stanley Smith Barney LLC. The notice was filed on 03/23/2026.
Sloat Tyler reported acquisition or exercise transactions in this Form 4 filing.
Hinge Health, Inc. director Tyler Sloat received an award of 9,896 shares of Class A Common Stock as a grant, reported at a price of $0.00 per share. After this transaction, he directly holds 9,896 shares.
The filing explains that these 9,896 shares are restricted stock units (RSUs), which vest in accordance with the terms of the award. Each RSU represents a contingent right to receive one share of Class A Common Stock, so the actual share delivery depends on future vesting conditions.
Hinge Health, Inc. director Tyler Sloat filed an initial ownership report on Form 3. This filing establishes his status as a director and discloses that there are no reportable transactions or derivative holdings included in this submission.
Hinge Health, Inc. has appointed Tyler Sloat to its Board of Directors as a Class I director, effective March 16, 2026. His term runs until the company’s 2026 annual stockholders’ meeting, and he will serve as Chair of the Compensation Committee and a member of the Audit Committee.
Sloat is currently Chief Operating Officer and Chief Financial Officer of Freshworks Inc. and previously served as CFO of Zuora Inc. He will receive standard non-employee director compensation, including an initial grant of RSUs valued at $400,000 vesting over three years, annual cash retainers for his board and committee roles, and eligibility for future annual RSU awards.
Hinge Health, Inc. Executive Chairman and Co‑Founder Gabriel M.I. Mecklenburg converted 166,666 shares of Class B Common Stock into an equal number of Class A shares on March 6, 2026 at a conversion price of $0.0000 per share. He then sold all 166,666 Class A shares in open‑market transactions at weighted average prices of $45.0224 and $45.6031, as part of a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. Following these transactions, he directly holds 1,843,102 shares of Class B Common Stock and has additional indirect Class B holdings through a GRAT and a family trust that are convertible into 1,092,119 and 383,592 shares of Class A Common Stock, respectively. The filing also notes 944,250 performance stock units held by Mecklenburg are excluded from these share counts.
Hinge Health, Inc. ownership update: Atomico Advisors IV, Ltd. and affiliated funds report beneficial ownership of 4,139,144 shares of Class A Common Stock, representing 5.1% of total outstanding equity based on 81,301,251 shares as of October 30, 2025.
The holding comprises (i) 3,376,865 shares held by Atomico IV L.P. (including 1,876,570 shares subject to a share collar dated December 8, 2025) and (ii) 762,279 shares held by Atomico IV (Guernsey), L.P. (including 423,430 shares subject to the same share collar).
Hinge Health, Inc. President James Pursley reported a tax-related share disposition. On March 1, 2026, he relinquished 5,127 shares of Class A Common Stock at a value of $42.76 per share. These shares were cancelled by the company to satisfy his federal and state tax withholding obligations from the vesting of restricted stock units. After this exempt tax-withholding transaction, Pursley directly owned 747,104 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. Chief Financial Officer James Budge reported a tax-related share disposition. On March 1, 2026, he relinquished 7,699 shares of Class A common stock at $42.76 per share, which were cancelled to cover federal and state tax withholding from vesting restricted stock units. After this exempt tax-withholding transaction, he beneficially owned 412,433 shares of Class A common stock.